Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month

Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for Evernorth’s employer and health plan clients.

Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month

Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductibleNew offering helps employers meet growing demand for FDA-approved weight loss medications at a lower net cost per…

Evernorth Launches Co-Pay Cap for Weight Loss Drugs Amid New Federal Drug Pricing Effort

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug pricing initiatives.

Cigna’s $200 Weight-Loss Drug Cap Shakes Up Hims & Hers Stock - Wall Street Pit

Hims & Hers Health Inc. (HIMS) declined 4.45% to $55.50, with an intraday low of $51.20, as Cigna’s (CI) Evernorth division introduced a $200 monthly cost cap for weight-loss drugs Wegovy and Zepbound. Evernorth’s pharmacy benefit plan enhances access to Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, with co-pays counting…